Nigro Olga, Chini Claudio, Marcon Ilaria Gioia Angiola, De Giorgi Annamaria, Bascialla Linda, Gallerani Elisa, Giaquinto Alice, De Palma Diego, Lombardo Maurizio
Medical Oncology.
Nuclear Medicine.
Dermatol Reports. 2022 Jul 12;14(3):9267. doi: 10.4081/dr.2022.9267. eCollection 2022 Sep 14.
Basal cell carcinoma (BCC) is the most common malignant tumor of the skin. Despite the indolent nature, metastatic BCC can occur, albeit rarely. Metastasis to the bone is very rare. From its approval, mBCC patients are treated with vismodegib, a selective hedgehog pathway inhibitor. Unfortunately, in recent period, it was demonstrated an emergence of drug resistance, due to Smoothened (SMO) mutation. To date, several groups are studying the effectiveness of immunotherapy in BCC. Clinical trials with Immune Checkpoint Inhibitors are ongoing. We report the rare case of a man with multiple bony metastasis, with a resistance to vismodegib, and we evaluated all manuscripts in literature reporting bone metastasis. Moreover, we review all the manuscripts in literature reporting bone metastasis, and we summarize the main therapeutic strategies, and the further perspectives.
基底细胞癌（BCC）是最常见的皮肤恶性肿瘤。尽管其生长缓慢，但转移性BCC仍可能发生，尽管极为罕见。骨转移非常少见。自获批以来，转移性BCC患者接受维莫德吉治疗，这是一种选择性刺猬信号通路抑制剂。不幸的是，最近发现由于 smoothened（SMO）突变出现了耐药性。迄今为止，多个研究团队正在研究免疫疗法在BCC中的有效性。免疫检查点抑制剂的临床试验正在进行中。我们报告了一例罕见的男性患者，他有多处骨转移，对维莫德吉耐药，我们评估了文献中所有报道骨转移的手稿。此外，我们回顾了文献中所有报道骨转移的手稿，总结了主要治疗策略及未来展望。
